Charles Wykoff, MD
Ophthalmology · Bellaire, TXNPI 1124237300
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,396,294 of the $1,533,128 with a category attached, or 91.1%. It is spread thinly across 47 manufacturers, the largest accounting for just 13.2%. Among ophthalmology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 743 payments — averaging $2063.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim International GmbH$202K
- Apellis Pharmaceuticals, Inc.$189K
- Eyepoint US, Inc.$143K
- Regeneron$128K
- Novartis Pharma AG$102K
- Regeneron Healthcare Solutions, Inc.$101K
- plus $667K from 41 others
Across 3,918 payments — averaging $18,377 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$29.2M
- Genentech, Inc.$27M
- Regeneron$9.5M
- Bayer$1.4M
- Ocular Therapeutix, Inc.$916K
- Apellis Pharmaceuticals, Inc.$869K
- plus $3.2M from 24 others
What the payments were for
- Consulting fees$1,396,29491%
- Speaking & faculty fees$96,8336%
- Travel & lodging$26,9322%
- Food & beverage$12,5481%
- Education$1080%
- Gifts$4130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYLEA$197,581
- EYP-1901$123,264
- BEOVU$92,787
- Syfovre$61,256
- OZURDEX$40,857
- Lucentis$29,685
- BLZ_BEOVU_OPHTHALMOLOGY$29,014
- ENCELTO$27,028
- YUTIQ$20,189
- Iluvien$19,847
- Non-Covered Product$17,251
- BVU_BEOVU_OPHTHALMOLOGY$15,050
- EYLEA HD$13,985
- SUSVIMO$12,953
- XIPERE$12,269
- TAKHZYRO$11,900
- RTH258A_BEOVU_OPHTHALMOLOGY$11,415
- VABYSMO$10,420
- VEOPOZ$6,630
- Izervay$3,800
How this compares
$1,533,128 in reported general payments places this provider in the 95th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 101 | $5,419 |
| Difluprednate | 23 | $3,612 |
| Ketorolac Tromethamine | 103 | $1,671 |
| Atropine Sulfate | 28 | $1,369 |
| Brimonidine Tartrate | 20 | $922 |
| Travoprost | 12 | $757 |
| Latanoprost | 71 | $501 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 53 | $439 |
| MoxifloxacinMoxifloxacin Hcl | 25 | $411 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 29 | $331 |
| Timolol Maleate | 13 | $77 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Bellaire
- Otis WaltonBellaire$311K
- Richard YeeBellaire$195K
- Prethy RaoBellaire$85K
- Hasenin Al-KhersanBellaire$76K
- Michael SingerSan Antonio$1.8M
- Oluwatosin SmithDallas$1.5M
- John MichelettiHouston$916K
- Davinder GroverDallas$705K
- Christina WengHouston$676K
- Peter ChangHouston$656K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.